Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate
NCT02288312 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18
Last updated 2015-01-08
Summary
Single-centre, open-label, randomised, gender-balanced, 3-way crossover, 3-period, 3-sequence study in 18 healthy male and female subjects.
Conditions
Interventions
- DRUG
-
BIA 2-093
Sponsors & Collaborators
-
Bial - Portela C S.A.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2007-05-31
- Primary Completion
- 2007-07-31
- Completion
- 2007-07-31
More Related Trials
-
A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures
NCT03116828 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures
NCT00957684 ·Status: COMPLETED ·Phase: PHASE3
-
Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine.
NCT02283801 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures
NCT01527513 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures
NCT00988429 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive
NCT00898560 ·Status: COMPLETED ·Phase: PHASE1
-
A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate
NCT02283814 ·Status: COMPLETED ·Phase: PHASE1
-
Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic
NCT01091662 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients
NCT01422720 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine
NCT00900237 ·Status: COMPLETED ·Phase: PHASE1
-
Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation
NCT02305329 ·Status: COMPLETED ·Phase: PHASE1
-
Anti-epileptogenic Effects of Eslicarbazepine Acetate
NCT06597084 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults
NCT02912364 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs
NCT00866775 ·Status: COMPLETED ·Phase: PHASE3
-
Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures
NCT02484001 ·Status: COMPLETED ·Phase: PHASE3
-
Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization
NCT02283788 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy
NCT00957047 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors
NCT02573272 ·Status: UNKNOWN
-
Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.
NCT02283827 ·Status: COMPLETED ·Phase: PHASE1
-
The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093
NCT02170649 ·Status: COMPLETED ·Phase: PHASE1
-
An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093
NCT02281526 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics, Efficacy and Tolerability of BIA 2-093
NCT02170064 ·Status: COMPLETED ·Phase: PHASE2
-
Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children
NCT00988156 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060
NCT06897683 ·Status: COMPLETED ·Phase: PHASE1
-
A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093
NCT02171195 ·Status: COMPLETED ·Phase: PHASE1